{
  "id": "6020b43a1cb411341a000087",
  "type": "summary",
  "question": "What is the role of phenylbutyrate\u2013taurursodiol for amyotrophic lateral sclerosis?",
  "ideal_answer": "Treatment of amyotrophic lateral sclerosis patients with phenylbutyrate\u2013taurursodiol was associated with both functional and survival benefits.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33063909",
    "http://www.ncbi.nlm.nih.gov/pubmed/32877582"
  ],
  "snippets": [
    {
      "text": "Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063909",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "An orally administered, fixed-dose coformulation of sodium phenylbutyrate-taurursodiol (PB-TURSO) significantly slowed functional decline in a randomized, placebo-controlled, phase 2 trial in ALS (CENTAUR). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Initiation of PB-TURSO treatment at baseline resulted in a 6.5-month longer median survival as compared with placebo. Combined with results from CENTAUR, these results suggest that PB-TURSO has both functional and survival benefits in ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877582",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: In this multicenter, randomized, double-blind trial, we enrolled participants with definite ALS who had had an onset of symptoms within the previous 18 months. Participants were randomly assigned in a 2:1 ratio to receive sodium phenylbutyrate-taurursodiol (3 g of sodium phenylbutyrate and 1 g of taurursodiol, administered once a day for 3 weeks and then twice a day) or placebo. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877582",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Sodium phenylbutyrate-taurursodiol resulted in slower functional decline than placebo as measured by the ALSFRS-R score over a period of 24 weeks. Secondary outcomes were not significantly different between the two groups. Longer and larger trials are necessary to evaluate the efficacy and safety of sodium phenylbutyrate-taurursodiol in persons with ALS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877582",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An orally administered, fixed-dose coformulation of sodium phenylbutyrate-taurursodiol (PB-TURSO) significantly slowed functional decline in a randomized, placebo-controlled, phase 2 trial in ALS (CENTAUR).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An orally administered, fixed-dose coformulation of sodium phenylbutyrate-taurursodiol (PB-TURSO) significantly slowed functional decline in a randomized, placebo-controlled, phase 2 trial in ALS (CENTAUR). Her",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33063909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Sodium phenylbutyrate-taurursodiol resulted in slower functional decline than placebo as measured by the ALSFRS-R score over a period of 24 weeks. Seco",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32877582",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}